Related ALXNYale University Is Bullish On ETFs & Alexion, Sold Twitter Last QuarterThe Dow Just Delayed A ‘Death Cross’The Vetr community has upgraded $ALXN to 4.5-Stars.(Vetr)Related CELGThe Historical Correlation Between Biotech Stocks And Interest Rates5 Biotechs With Catalysts Coming This WeekWeak Market? Don’t Tell That To Google, Celgene(Investor’s Business Daily)By and large, the number of shares short in the leading […]
By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
By Ben LevisohnBarclays’ Geoff Meacham and Jonathan Eckard are feeling good about biotech stocks like Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) heading into the summer. They explain why:
Associated Press
[The] Nasdaq Biotech Index index has outperformed the broader market eight out of 10 times over the summer period (Memorial Day to Labor Day) and in 2Q/3Q, there are a number of meaningful […]
Mergers & acquisitions once again took center stage in the biotech sector with Alexion (ALXN – Analyst Report) announcing its intention to acquire Synageva (GEVA – Snapshot Report). Meanwhile, there were some important updates on the regulatory and pipeline front from companies like Vertex (VRTX – Analyst Report) and Orexigen (OREX – Analyst Report).Recap of the Week’s Most Important Stories1. […]
Update 1/27 After the Close Amgen Beats
Amgen, Inc (AMGN) fourth quarter earnings and sales beat estimates on strong sales of Enbrel, an arthritis drug.Revenue for Q4 was $5,33B a 6% increase over Q4 2013, The stock was up slightly after hours to $159.40. Sales growth was also driven by Kyprolis and Prolia. The P/S is still a modest 6.12 and […]
Three of nine sectors moved higher on Wednesday…XLU, XLV and XLI were the strongest sectors and XLE was the weakest.Breadth was mixed as decliners led advancers 1.06 to 1 onthe NYSE and advancers led decliners 1.42 to 1 on the NASDAQ.Wednesday – mixed, mixedTuesday – mixed, advancers ledMonday – strengthened, advancers ledFriday – weakened, advancers ledThursday – weakened slightly, advancers […]
Eight of nine sectors moved higher on Tuesday…XLE, XLB and XLP were the strongest sectors and XLV was the weakest.Breadth strengthenedon the NYSE as advancers led decliners…1.83 to 1 on the NYSE and 1.04 to 1 on the NASDAQ.Tuesday – mixed, advancers ledMonday – strengthened, advancers ledFriday – weakened, advancers ledThursday – weakened slightly, advancers ledWednesday – strengthened, advancers ledSPY […]
By Ben LevisohnLeerink’s Howard Liang and team think 2015 will be another good year for biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Amgen (AMGN ) and Alexion Pharmaceuticals (ALXN). They explain why:
Boston Globe via Getty Images
Biotech fundamentals appear strong, and could attract and broaden investor interest in the sector. Ongoing and upcoming product launches could be among the fastest […]
With the holiday season coming up, it’s been a relatively quiet week for the biotech sector with very few pipeline and regulatory updates. However, companies like Sophiris (SPHS – Snapshot Report) and Cyclacel saw their shares plunging on disappointing pipeline updates.Recap of the Week’s Most Important Stories1. Sophiris faced a major pipeline setback following an interim analysis of an ongoing […]
By Ben LevisohnYes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:
October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years. We believe […]
